Clinical trials
Recruiting Phase 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 21 |
| 2025 | 15 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 65 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| City of Hope Medical Center | 4 |
| M.D. Anderson Cancer Center | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| The First Affiliated Hospital of Zhengzhou University | 4 |
| First Affiliated Hospital of Zhejiang University | 3 |
| Fred Hutchinson Cancer Center | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| St. Jude Children's Research Hospital | 3 |
| Northside Hospital, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 65 |
| Leukemia, Myeloid, Acute | 21 |
| Myelodysplastic Syndromes | 18 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 |
| Lymphoma, Non-Hodgkin | 10 |
| Myeloproliferative Disorders | 9 |
| Burkitt Lymphoma | 8 |
| Hodgkin Disease | 8 |
| Leukemia, Biphenotypic, Acute | 7 |
| Leukemia, Myelomonocytic, Chronic | 7 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.